Straits Times Index
3,087.95 -22.78 (-0.73%) Nikkei
32,771.06 +463.20 (+1.43%) Hang Seng
16,017.49 -316.88 (-1.94%) FTSE 100
7,554.47 +40.75 (+0.54%) Bitcoin USD
42,375.31 -1,434.29 (-3.27%) CMC Crypto 200
873.82 -22.89 (-2.55%)
REGN Jan 2024 650.000 put
| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 650.00 |
| Expiry date | 2024-01-19 |
| Day's range | 0.8000 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 123 |
GlobeNewswireLatest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR Oral presentation showcased overall maintenance of patient-reported outcomes from baseline to 50 weeks during investigational odronextamab treatment, complementing the overall efficacy and safety profile in this heavily pretreated and highly refractory patient population TARRYTOWN, N.Y., Dec. 10, 2023 (GLOBE
- GlobeNewswire
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate (ORR), with 31% achieving a complete response (CR) Results from a Phase 1 expansion cohort showed a 48% ORR and 30% CR in patients who had progressed on CAR-T Additional exploratory data from the Phase 2 trial presented in an oral session showed an association between circulating tumor DNA (ctDNA) negativity and progression-free survival TARRYTOWN, N.Y., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Reg
ZacksRegeneron (REGN) Posts Positive Data on Blood Cancer Candidate
Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.
